ESP Picks Up J&J's Retavase On Heels Of Protein Design Labs Merger Deal

The thrombolytic will be promoted by ESP's 75-member sales force, which currently details the antihypertensive Cardene IV. PDL's pending acquisition of ESP, originally valued at $475 mil., with get a $25 mil. boost from the Retavase deal.